Susanne Stowasser
Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany
Ingelheim Am Rhein, RP 55216, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.
Journal: American journal of respiratory and critical care medicine
Published: March 02, 2026
Effect of nerandomilast on survival in patients with pulmonary fibrosis.
Journal: The European respiratory journal
Published: February 13, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.
Journal: Annals of the rheumatic diseases
Published: December 23, 2025
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
Journal: The European respiratory journal
Published: September 10, 2025
Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis.
Journal: ERJ open research
Published: July 18, 2025
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Journal: The New England journal of medicine
Published: May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary Fibrosis.
Journal: The New England journal of medicine
Published: May 19, 2025
Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 23, 2025
Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good.
Journal: American journal of respiratory and critical care medicine
Published: May 31, 2024
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.
Journal: Journal of comparative effectiveness research
Published: December 20, 2022
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF).
Journal: BMJ open respiratory research
Published: November 23, 2022
Last Updated: 09/26/2026